Q32 Bio Stock Today
| QTTB Stock | 27.04 0.24 0.88% |
Performance0 of 100
| Odds Of DistressOver 53
|
Q32 Bio is trading at 27.04 as of the 21st of November 2024, a 0.88 percent decrease since the beginning of the trading day. The stock's open price was 27.28. Q32 Bio has 53 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Q32 Bio symbol was changed from FIXX on 26th of March 2024. Equity ratings for Q32 Bio are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 22nd of October 2024 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of March 2018 | Category Healthcare | Classification Health Care |
Q32 Bio is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 12.06 M outstanding shares of which 686.07 K shares are at this time shorted by private and institutional investors with about 3.65 trading days to cover. More on Q32 Bio
Moving against Q32 Stock
Q32 Stock Highlights
| Older Symbol | FIXX | ||||
| Secretary CEO | Jodie Morrison | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Q32 Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Q32 Bio's financial leverage. It provides some insight into what part of Q32 Bio's total assets is financed by creditors.
| |||||
Q32 Bio (QTTB) is traded on NASDAQ Exchange in USA. It is located in 830 Winter Street, Waltham, MA, United States, 02451 and employs 42 people. Q32 Bio was previously known as Homology Medicines and was traded on NASDAQ Exchange under the symbol FIXX. Q32 Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 556.56 M. Q32 Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 12.06 M outstanding shares of which 686.07 K shares are at this time shorted by private and institutional investors with about 3.65 trading days to cover.
Q32 Bio generates negative cash flow from operations
Check Q32 Bio Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Q32 Bio is USD556.56 Million. The majority of Q32 Bio outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to secure positions in Q32 Bio to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in Q32 Bio. Please pay attention to any change in the institutional holdings of Q32 Bio as this could imply that something significant has changed or is about to change at the company. Note, that even with negative profits, if the true value of the entity is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Q32 Ownership Details
Q32 Bio Historical Income Statement
Q32 Stock Against Markets
Q32 Bio Corporate Management
| Saul Fink | Chief Officer | Profile | |
| Kathryn MBA | Manufacturing Chemistry | Profile | |
| Lee MBA | Chief Officer | Profile | |
| Maria MPH | Executive Operations | Profile | |
| David JD | Senior People | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Q32 Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. If investors know Q32 will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Q32 Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.50) | Revenue Per Share (1.24) |
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Q32 Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Q32 Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Q32 Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.